Pharmacogenetics of development of inhibitory antibodies to factor VIII hemophilia A
The most serious complication of factor VIII (FVIII) replacement therapy in patients with hemophilia A is the development of inhibitory alloantibodies or autoantibodies. The inhibitory antibodies impair effective hemostasis, representing real risk for hemorrhagic episodes difficult to control. This...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2011 |
| País: | Brasil |
| Institución: | Faculdade de Medicina de Campos (FMC) |
| Repositorio: | Revista Científica da Faculdade de Medicina de Campos |
| Idioma: | portugués |
| OAI Identifier: | oai:ojs.www.fmc.br:article/106 |
| Acceso en línea: | https://www.fmc.br/ojs/index.php/RCFMC/article/view/106 |
| Access Level: | acceso abierto |
| Palabra clave: | fator VIII hemofilia A inibidores resposta imune factor VIII hemophilia A inhibitors immune response |
| Sumario: | The most serious complication of factor VIII (FVIII) replacement therapy in patients with hemophilia A is the development of inhibitory alloantibodies or autoantibodies. The inhibitory antibodies impair effective hemostasis, representing real risk for hemorrhagic episodes difficult to control. This revision addresses the pertinent concepts, and covers the following pharmacogenetic aspects of the development of inhibitory antibodies: antibody types, inhibitory mechanisms, diagnostics, genetic and non-genetic risks factors, alternatives of treatment and intervention. |
|---|